Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

National Center for Rehabilitative Auditory Research (NCRAR)

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

Marilyn Dille, Ph.D.

Telephone:  503-220-8262, ext. 56428
E-Mail:  marilyn.dille@va.gov 

Current appointments

NCRAR Research Investigator
Assistant Professor, Department of Otolaryngology/H&N Surgery, Oregon Health & Science University

Research Interests

Hearing monitoring when ototoxic agents are used to treat Veterans with serious illnesses such as cancer or infections, effects of diabetes type 2 on the auditory system from the periphery to cognition, changes in hearing and sound processing abilities due to increasing age, development of hearing test devices that can be used in the field to detect early changes in hearing or cochlear function due to noise or to ototoxic agent exposure.

Current and Recently Completed Research Projects

Comprehensive Ototoxicity Monitoring for VA Healthcare: A randomized trial
Principal Investigators: Marilyn Dille, Ph.D., Dawn Konrad Martin, Ph.D.
Rehabilitation Research & Development Service (4/01/14-3/31/18)
 
Longitudinal Changes in Auditory Function Among Veterans with Diabetes
Principal Investigators: Dawn Konrad Martin, Ph.D., Marilyn Dille, Ph.D.
Rehabilitation Research & Development Service (4/01/15-3/31/19)
   
Longitudinal Changes in Auditory Function Among Veterans with Diabetes
Principal Investigators: Dawn Konrad Martin, Ph.D., Marilyn Dille, Ph.D.
Rehabilitation Research & Development Service (1/01/11-12/31/14)
             
Rapid assessment methods for early detection of hearing impairment
Site Investigator: Marilyn Dille, Ph.D.
Department of Defense, CDMRP (9/01/13-03/15/14)

A Portable Audiometric Monitoring Device (the OtoID)
Principal Investigators: Marilyn Dille, Ph.D.
Rehabilitation Research & Development Service (7/01/08-9/31/13)

Individualized Objective Techniques for Early Detection of Ototoxicity
Principal Investigators: Marilyn Dille, Ph.D., Dawn Konrad Martin, Ph.D.
Rehabilitation Research & Development Service (7/01/10-9/3/13)

Selected Publications:

Konrad-Martin D, Reavis KM, Austin D, Reed N, Gordon J, McDermott D, Dille MF. Hearing Impairment in Relation to Severity of Diabetes in a Veteran Cohort. Ear Hear. 2015 Jul-Aug;36(4):381-94.

Reavis KM, McMillan GP, Dille MF, Konrad-Martin D. Meta-Analysis of Distortion Product Otoacoustic Emission Retest Variability for Serial Monitoring of Cochlear Function in Adults. Ear Hear. 2015 May 14.

Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):81-100.

Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring. J Am Acad Audiol. 2013 Oct;24(9):769-81.

McMillan GP, Reavis KM, Konrad-Martin D, Dille MF. The statistical basis for serial monitoring in audiology. Ear Hear. 2014 Mar-Apr;35(2):286-294.

Dille MF, Jacobs PG, Gordon SY, Helt WJ, McMillan GP. OtoID: new extended frequency, portable audiometer for ototoxicity monitoring. J Rehabil Res Dev. 2013;50(7):997-1006.

Jacobs PG, Silaski G, Wilmington D, Gordon S, Helt W, McMillan G, Fausti SA, Dille M. Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics. IEEE Trans Biomed Eng. 2012 Nov;59(11):3097-103.

McMillan GP, Konrad-Martin D, Dille MF. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes. Int J Audiol. 2012 Sep;51(9):689-96.

Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J Am Acad Audiol. 2012 Jul-Aug;23(7):510-21.

Konrad-Martin D, Reavis KM, McMillan GP, Dille MF. Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring. Int J Audiol. 2012 Feb;51 Suppl 1:S51-62.

Konrad-Martin D, Dille MF, McMillan G, Griest S, McDermott D, Fausti SA, Austin DF. Age-related changes in the auditory brainstem response. J Am Acad Audiol. 2012 Jan;23(1):18-35.

Dille MF, McMillan GP, Reavis KM, Jacobs P, Fausti SA, Konrad-Martin D. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model. J Acoust Soc Am. 2010 Sep;128(3):1163-74.

Dille MF, Konrad-Martin D, Gallun F, Helt WJ, Gordon JS, Reavis KM, Bratt GW, Fausti SA. Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study. J Am Acad Audiol. 2010 Jun;21(6):409-17.

Ellingson RM, Dille ML. Dynamic range considerations when designing PC sound card based audiometric systems to test human hearing. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:5907-10.

Ellingson RM, Dille ML, Leek MR, Fausti SA. On the synthesis of multiple frequency tone burst stimuli for efficient high frequency auditory brainstem response. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:4158-61.

Dille M, Glattke TJ, Earl BR. Comparison of transient evoked otoacoustic emissions and distortion product otoacoustic emissions when screening hearing in preschool children in a community setting. Int J Pediatr Otorhinolaryngol. 2007 Nov;71(11):1789-95.

Recent Presentations

Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA) Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Audiology Grand Rounds, Oregon Health and Science University, Podium Presentation, 2015, Portland, OR.

Auditory and cognitive effects of diabetes: Influence of disease severity. Reed NS, Dille M, Reavis K, Austin D, McDermott D, Gordon J, Konrad-Martin D. American Auditory Society Annual Conference. Poster Presentation. 2014, Scottsdale, AZ.

Long-term variability of distortion product otoacoustic emissions (DPOAE) in children. Knight KR, McMillan GP, Martin D, Nelson E, Neuwelt E, Winter C, Dille M. American Auditory Society Annual Conference. Poster Presentation. 2014, Scottsdale, AZ.

Ototoxicity monitoring program: An evidence-based technique and application. Ortiz CE, Dille M, Walden TC. Joint Defense VA Audiology Annual Conference. Podium Presentation, 2014, Las Vegas, NV.

Evidence-based techniques and time efficient tools for ototoxicity monitoring programs. Dille MF, Reavis KM, Helt WJ, McMillan GP, Konrad Martin D. Association of VA Oncology and Hematology Annual Conference, Poster Presentation 2013, Atlanta, GA.

Pre-Treatment ototoxicity risk assessment for Veterans prescribed cisplatin. Helt WJ, Dille MF, Reavis KM, McMillan GP, Konrad Martin D. Association of VA Oncology and Hematology Annual Conference, Poster Presentation 2012, Omaha, NE.

A new portable telehealth device for ototoxicity monitoring, the OtoID. Dille M, Konrad Martin D, Helt WJ, Reavis K, Gordon S, McMillan GP. Association of VA Oncology and Hematology Annual Conference, Podium  Presentation 2012, Omaha, NE

Quick, easy and accurate tests for cisplatin ototoxicity. Dille MF, Reavis KM, Konrad Martin D, McMillan GP. Joint Defense VA Audiology Annual Conference, Podium Presentation, 2012, Dallas, TX.

For additional information on research, presentations and publications, please contact me to request a CV.